Clinical IP Commercialization Program Brings IT Ideas to Clinics

Kafka Adaptive collaborates closely with clinicians in the design of clinical information collection, management and analysis technologies, often producing surprising advances. A number of these innovations, the company has found, are applicable to many clinical environments, and have given rise to some of the finished products the company is now bringing to market on behalf of its development partners.

Professor John Monson, of St Bartholomew's Hospital in London, described his centre of excellence's development experience with Kafka Adaptive:

"They didn't come in with any pre-conceived ideas. . . They just listened and delivered exactly what we had asked for - but with much more [depth of technical detail] that we didn't know we actually needed."

To codify its development experience and expertise, Kafka Adaptive inaugurated its Clinical Intellectual Property Commercialization Program (CIPCP). CIPCP has one imperative: to fast track the launch of clinical IT product lines based on clinicians' own designs - and on the specific, immediate market needs of the clinical discipline being addressed.

Kafka Adaptive develops products, and wholly-new enterprises, based on the best thinking from world-renowned clinicians - across the globe. Clinicians see their IP come to life as vital technologies that their colleagues will value - and their patients benefit from. Most importantly, these products are brought to market by Kafka Adaptive's hard-won marketing expertise - with new companies that Kafka Adaptive helps create in tandem with clinicians - or through IBM's Life Sciences initiative.

Dr. Martin Teicher, Director of Psychopharmacology at McLean Hospital and Harvard University Medical School Professor, says of Kafka Adaptive and our development process:

"These guys are scientific."

In this way, Kafka Adaptive is continuing a practice its principals have been animating all their professional lives - as engineers and marketing professionals at Lotus Development, IBM and other world-leading software organizations. In the CIPCP assessment and development process, Kafka Adaptive principals follow a proven methodology that has brought two vital behavioral diagnostics offerings to market-readiness in the six months between November 2002 and May 2003 alone.

1. IP and Pre-IP Vetting

Kafka Adaptive considers the idea or intellectual property for its essential technical viability, given its cost of development as well as contemporary infrastructures and legacy technology barriers. KA’s principals are not clinicians - but they are expert in IT usage patterns as well as acceptance barriers in clinical environments.

2. Market Viability Assessment

Kafka Adaptive considers the innovation's viability as an IT asset, determining the potential scope of its addressable markets and the cost effort required for selling into such markets. This helps inform marketing decisions and, at the same time, size the attendant opportunities for potential investors and channel partners.

3. Rapid prototype design and delivery

Kafka Adaptive designs the working prototype of the product, based on the clinician's ideas. Those concepts are informed and tempered by Kafka Adaptive's own technological assessment as well as the clinical requirements of the market cohort to which the new product is being targeted.

4. Go-To-Market Plans

Kafka Adaptive develops the real-world and cost-effective marketing plan that will deliver the new clinical IT offerings to markets nationally and globally in the shortest possible timeframes. As time is of the essence, we preferentially develop technologies for which a strong and provable market need already exists.

5. Go-To-Market Execution

Kafka Adaptive animates the marketing mechanisms that will deliver the new clinical IT offerings to markets nationally and globally in the shortest possible time frames. Kafka Adaptive might re-badge technology under its own name, cross-license with the innovator and spin-out a new company that divides its revenues between the innovators and Kafka Adaptive - or develop the technology on a fee-for-service basis - or through whatever win-win models works.

Clinical innovations that deliver smarter, more elegant data collection, management and distribution are all part of the brief at CIPCP. For example we are working with a major psychiatric teaching hospital to commercialize diagnostic and monitoring software and patient telemetrics for ADHD-affected children and bipolar patients. At the same time, we've organized a company to offer quick and easy neuropsych testing systems to measure school children's learning and management competencies.

Finally, to leverage the special R&D funding opportunities available to clinicians, Kafka Adaptive can help clinical investigators organize grant applications with government public health agencies and private foundations. The companies marketing and development divisions can provide immediate technical expertise to drive grant-funded development. Kafka Adaptive can work as the lead developer in some grant programs - or as a sub-contractor providing critical technical expertise. What's more, Kafka Adaptive, given its working presence in both the US and the UK, is eligible to participate in grants-making programs in the United States and Europe.

Tell us the IP or ideas that you've got. Tell us what would be magic in the clinical environments you inhabit. In a few months your colleagues could be using them to the benefit of their practices and their patients, another CIPCP contribution to the clinical data logistics disciplines.


When Data Architectures Become the Solution

Clinical IP Commercialization Program Brings
IT Ideas to Clinics